About Predicine
Predicine is a company based in Hayward (United States) founded in 2015 by Shidong Jia and Du Pan. Predicine has raised $41.31 million across 4 funding rounds from investors including Honghui Fund, Sangel Capital and Highlight Capital. The company has 23 employees as of December 31, 2017. Predicine offers products and services including PredicineATLAS™, PredicineCARE™, PredicineRNA™, and PredicineHEME™. Predicine operates in a competitive market with competitors including Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Hayward, United States
- Employees 23 as on 31 Dec, 2017
- Founders Shidong Jia, Du Pan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Predicine, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$41.31 M (USD)
in 4 rounds
-
Latest Funding Round
$14.28 M (USD), Series B
Jul 29, 2020
-
Investors
Honghui Fund
& 2 more
-
Employee Count
23
as on Dec 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Predicine
Predicine offers a comprehensive portfolio of products and services, including PredicineATLAS™, PredicineCARE™, PredicineRNA™, and PredicineHEME™.
Genomic assay for detecting TMB and MSI in cancer patients.
Assay for identifying fusion and splicing in cancer genomics.
Platform for analyzing RNA in blood for cancer detection.
Test for genetic alterations in hematological cancers.
People of Predicine
Unlock access to complete
Funding Insights of Predicine
Predicine has successfully raised a total of $41.31M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.28 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Predicine
Predicine has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Honghui Fund, Sangel Capital and Highlight Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare startups are funded by HLC venture capital firm.
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Private equity and early-stage venture capital firm investing primarily in Chinese companies
|
Locked | Locked | Locked |
Investor details for Predicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Predicine
Investment portfolio details for Predicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Predicine
Detailed financials for Predicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Predicine Comparisons
Peer comparison for Predicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Predicine
Predicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of Predicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Predicine
Complete news archive for Predicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Predicine
Predicine was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Predicine is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Shidong Jia is the current CEO of Predicine. They have also founded this company.
Predicine is a funded company, having raised a total of $41.31M across 4 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Predicine is 23.
Predicine was founded in 2015 and is headquartered in Hayward, United States. Operations are centered in the biotechnology sector, with a focus on oncology diagnostics. Liquid biopsy assays are developed through the proprietary Gene RADAR platform, which supports simultaneous detection and characterization of cell-free DNA and cell-free RNA from body fluids. Biomarker discovery services are also provided to advance cancer research and treatment strategies.
Predicine's top competitors include Guardant Health, GRAIL and BillionToOne.
Predicine offers PredicineATLAS™, PredicineCARE™, PredicineRNA™, and PredicineHEME™.
Predicine has 3 investors. Key investors include Honghui Fund, Sangel Capital, and Highlight Capital.